South Korean pharmaceutical company Celltrion has launched two oncology drugs in Vietnam, marking a significant step in its Southeast Asian market expansion. The launched products are Truxima, a treatment for blood cancer containing rituximab, and a drug for metastatic colorectal and breast cancer. This move aims to bolster Celltrion’s presence in the rapidly growing Vietnamese pharmaceutical sector. The company anticipates increased accessibility to vital cancer treatments for Vietnamese patients. This launch follows approvals from Vietnamese health authorities and aligns with Celltrion’s broader strategy to penetrate emerging markets. Celltrion intends to leverage Vietnam as a key hub for further distribution throughout the region. The company expects these launches to contribute positively to its revenue growth and global market share.